17:55 EST Vertex Pharmaceuticals (VRTX) up 2% at $448 after FDA Journavx approval
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals’ non-opioid painkiller approved by FDA, Bloomberg says
- Vertex Pharmaceuticals’ non-opioid Journavx approved for pain by FDA
- Meta Platforms, CVS Health upgraded: Wall Street’s top analyst calls
- Wells downgrades Vertex to Equal Weight on lack of catalysts
- Vertex downgraded to Equal Weight from Overweight at Wells Fargo